Virtual Seminars

Bring Upperton into your Meeting Room

Upperton offer companies virtual on request seminars based upon our experience and expertise that have created the foundation to Upperton’s CDMO services. These will be brought to you by Upperton’s Subject Matter Experts. A number of topics are included below as suggestions but if you have a specific topic you wish to discuss let us know and we will prepare a tailored seminar to suit your particular challenge.

The Premise

The seminars consist of an interactive presentation of twenty minutes followed by questions and answers. They will be hosted on Zoom conference calling, by the speaker from Upperton. The link will be accessible by up to 100 remote users from your company. From request, it may take up one week to schedule your virtual seminar.

Topics Include

Improved Bioavailability Using Enabling Technologies to Improve Solubility

Low bioavailability is a major cause for the failure of many early phase clinical trials. It is therefore obvious that low bioavailability risk mitigation must occur during the earlier stages of drug formulation development in order to reduce time to clinic, maximise development budgets and halt the premature dropping of promising molecules. This webinar will cover several different enabling technologies that can improve the solubility of your dosage form and potentially its subsequent bioavailability. It will also outline Upperton’s enabling technology screening protocol (UpperSolv™) which can assist in identifying the formulation strategy that offers the best chance of success in the clinic using limited API.

Tablet Formulation Development

Tablets continue to be one of the most popular pharmaceutical dosage forms, as with the right tablet formulation you can achieve: ease of handling and administration for patients, stability convenient packing options, and well-established cost-effective manufacturing processes which produce consistent quality products. There are many different types of tablets and drug-release technology that can be applied to the formulation. This topic will cover the types, formulation strategies and manufacturing processes of tablets.

Scaling-up Process for Inhaled Delivery

For successful pulmonary delivery of dry powder inhaled (DPI) formulations, the production of small particles with an aerodynamic particle size between 1-5 μm is required to reach the deep lung. There are a number of techniques that can be used to achieve this size range with spray drying being seen as a manufacturing method capable of producing spherical particles with excellent control of size, morphology and aerosolisation behaviour. This seminar will cover how to create particles for optimum pulmonary delivery through careful selection of both the formulation, solution and spray drying parameters.

Applications of Spray Drying

Spray drying is used extensively in the pharmaceutical industry with an ever-growing list of applications. It is widely regarded as the most flexible formulation technology for enhancing the delivery of APIs and larger biomolecules. The rapid growth of pharmaceutical spray drying has been fuelled by its ever-expanding list of applications. However, its flexibility is not its only strength. The simplicity, reproducibility and scalability of the spray drying process, has resulted in it becoming the fastest growing processing technology in the pharmaceutical industry. This seminar will cover the key applications, benefits and features of spray drying.

Dry Powder Formulations for First-in-Human Studies

Before the final dosage form can be developed there is significant pressure to generate early clinical data with the API. This pressure is often driven by commercial and business considerations, with early safety and PK data required to justify further internal or external funding, or to put more succinctly “does this API work and can I justify spending more money on it?”. Allied to the time and costs for developing a formulation it is important to bear in mind some of the process specific characteristics which in turn will have an impact on the choice of FIH dosage form. The key formulation considerations, advantages and disadvantages of: powder in a bottle, capsules and tablets will be covered.

General Overview of Upperton’s Capabilities

Upperton is a CDMO that can, within days of initial contact, start feasibility studies with only a few milligrams of a client’s drug candidate. We offer our clients a complete development package, across all dry powder dosage forms: powders, capsules, tablets, devices for nasal and pulmonary delivery.  With experience of working on a range of dosage forms and the expertise to develop the most challenging molecules. 

Nasal Drug Delivery – A non-invasive route to local and systemic treatments

Nasal drug delivery offers fast action, with a direct route to the brain whilst avoiding first past metabolism and olfactory delivery. It’s a useful method of systemic delivery with molecules being absorbed within the nasal cavity through the use of absorption enhancers. While also having the ability for local delivery by targeting the nose and nasal cavity.

This list is not exhaustive, if through reading Upperton’s articles or being aware of our expertise and experience, Upperton will welcome suggested topics which interest you and your company most. Click here to read Upperton’s released articles.


Richard Johnson
Founder & CEO

Dr Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Richard previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix). Richard holds an honours degree in Biology from University of York and a Ph.D. from the University of Warwick and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.

Ian Lafferty
Technical Director

Dr Ian Lafferty has 25 years’ technical and operational experience in early phase pharmaceutical development encompassing the formulation design, development, process optimisation and manufacture of a wide range of dosage forms including oral solids, inhaled powders, suspensions and injectables with a focus on challenging molecules, enabling technologies and high potent handling.  He also has significant experience in facility design and management.

Ian has held senior roles at several emerging and growing CDMOs providing strategic and operational leadership to ensure excellence in all aspects of providing pharmaceutical services.